Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AMRI Realigns Its Discovery Services
by Ann M. Thayer
December 10, 2012
| A version of this story appeared in
Volume 90, Issue 50
Albany Molecular Research Inc. will fold its in vitro biology capabilities into its other drug discovery services. In the process, the firm will close its Bothell, Wash., site, which employs 24 people, by March 2013. The company will move most of the site’s activities to its Singapore location and certain analytical capabilities to its Albany headquarters. Earlier this year, AMRI trimmed its U.S. contract drug discovery staff, closed a site in Hungary, and expanded in India and Singapore.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter